Clinical trial

Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events

NCT01110291

Study summary

ClinicalTrials.gov

Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention docetaxel + CEF Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2003-04-01

PhaseN/A

Conditions

CYP3A Phenotypingunresolved

CYP3A5 and MDR1 Genotypingunresolved

Docetaxel Toxicityunresolved

Associations Between Genetic Data and Docetaxel Toxicityunresolved

Interventions

docetaxel + CEFDRUG

Sponsors & collaborators

University of Turkulead sponsor

Sanoficollaborator

Turku University Hospitalcollaborator

Vaasa Central Hospital, Vaasa, Finlandcollaborator

medbase Oy Ltdcollaborator

Mapped research locations

TurkuFinland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01110291 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.